CPS HR Consulting Announces Katrina Hagen as New CEO Amid 40th Anniversary Milestone
CPS HR Consulting Announces Katrina Hagen as New CEO Amid 40th Anniversary Milestone
Share
Following a detailed search and a thorough selection process, Hagen was chosen for her extensive public sector experience and visionary leadership in workforce development. She officially assumes the role on July 7, 2025.
Hagen brings more than 25 years of public service leadership to CPS HR. Most recently, she served as director of the California Department of Industrial Relations, where she oversaw more than 3,500 employees and led efforts to protect worker rights, safety and compensation. Her previous leadership roles at CalHR, CalPERS and CDTFA have positioned her as a trailblazer in HR modernization and public workforce strategy.
'As we celebrate our 40th anniversary, CPS HR is thrilled to welcome a leader of Katie's caliber,' said the CPS HR Board of Directors. 'Her experience and passion for public service perfectly align with our mission to elevate HR practices in government agencies across the country.'
Hagen holds a Masters of Public Administration from the University of San Francisco and a Bachelor of Arts in Political Science and French from Humboldt State University. She has also contributed to the next generation of public service leaders as an adjunct faculty member in MPA and organizational behavior programs at USF.
The board expressed confidence that Hagen will build on the organization's legacy while bringing new energy to its strategic vision. Her appointment marks a significant milestone for the Sacramento-based agency as it looks ahead to the next 40 years of innovation in public sector human resources.
About CPS HR Consulting
CPS HR Consulting, based in Sacramento, California, is a self-supporting public agency providing a full range of comprehensive HR solutions to government and nonprofit clients across the country. CPS HR consultants have expertise in the areas of organizational strategy, recruitment and selection, classification and compensation, and training and development. For more information, visit www.cpshr.us or connect with them on LinkedIn, Twitter, and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
a few seconds ago
- San Francisco Chronicle
S.F.'s Ferry Building is transforming. This new restaurant shows its dining future
In 2003, the promise of the restored Ferry Building was clear. The ground floor, formerly used for storage, was reimagined as a bustling market hall where culinary flâneurs could nibble and browse, whether they were catching a ferry or not. Lining the retail concourse were a cheese stall, a bread stand, a butcher counter — the departments of your local grocery store, but better. Quickly, it became a destination. Now, change is afoot. The Ferry Building management's new strategy appears to be modeled less on Safeway and more on Stonestown, the San Francisco mall filling its storefronts with restaurants that are destinations in their own right. Grand Crêperie, an unassuming French bistro that I thought of as 'the crêpe place,' did not have its lease renewed, for example. Coming soon? Full-service restaurants from the teams behind A16 and Michelin-starred Sorrel. Daytime foot traffic may be at an all-time high, with office workers and tourists queued up for soft serve and sandwiches. But happy hour and dinnertime have yet to be conquered, and no one is going to plan a night out around a cute crêpe place. In the hopes of luring locals to the Embarcadero in the evenings, the Ferry Building is focusing on marquee restaurants with pedigree. Nopa Fish is exactly the type of tenant the new, took-her-hair-down-and-switched-to-contacts Ferry Building is banking on. Until 2020, Nopa Fish's space was occupied by another fishmonger, the San Francisco Fish Company, a name so generic I have already forgotten it. Nopa Fish provides the same services — fresh fish in the case, hot food made to order and, soon, prepared foods to-go — but this time, with name brand recognition. Nopa, on the corner of Divisidero and Hayes, has been a literal neighborhood-defining restaurant since 2006. It's the type of place that friends visiting from out of town will have saved on a decade-old Google map, inquiring, 'What about Nopa, is it still good?' (It is.) Chef Laurence Jossel — who, after a post-pandemic shakeup, is now the sole owner — had been considering opening another concept when one of his longtime seafood suppliers, Joe Conte of Water2Table, approached him with the Ferry Building opportunity. Jossel didn't take long to decide that, in his words, 'this would be a stupid thing to turn down.' As of now, about 85% of Nopa Fish's revenue comes from the restaurant side of the business, although Jossel and his partner, Holly Rhodes, expect fresh fish sales to increase once they open earlier to coincide with the morning farmers market rush. For now, lunch is the main attraction. If Jossel was serving corn chowder and corn chowder alone, it would be reason enough to stop by ($10 for a cup, $15 for a bowl). The seafood element is morsels of McFarland Springs trout, brined in molasses and beer before Jossel smokes it over cherry wood. The corn kernels retain a bit of a snap — no mushfest here — and the whole hearty jumble is drizzled with a potent basil pesto. Come fall, corn will make way for mushrooms, or maybe squash. Fish and chips ($25 for three pieces of sustainably caught local rockfish) are requisite fish counter fare, punched up. While I didn't much detect the ras el hanout in the batter, which Jossel says is a tribute to Nopa's popular Moroccan fried chicken, the overall spice profile of the dish rings loud and clear with toasted cumin fries, turmeric pickles and harissa aioli. Fried rockfish also appears on a veg heavy, bánh mì-inspired sandwich ($21). Opt for it, if you're in a bready mood, over the open-faced bay shrimp and egg salad sandwich ($17), which features feather-soft milk bread that offers little resistance to the gloppiness of the topping. While Jossel, who is currently at Nopa Fish every day, oversees the kitchen, the fish case is the domain of Nate Li. With over 17,000 followers on Instagram, Li is a certified 'fish-cutting celebrity,' Jossel says. In his videos, which I can best describe as ASMR for butchery freaks, @mrniceguy415 breaks down halibut, black cod and bluefin tuna, displaying the translucent carcasses to the camera, not a scrap of flesh left behind. A former employee of Water2Table, Li has exacting standards. 'He's not afraid to turn fish away,' Jossel says. 'If it's not good enough for Nate, it's not going in the case.' Li and Jossel's combined talents reach their pinnacle in Nopa Fish's chirashi bowl, listed on the menu as 'pristine fish over sushi rice' ($26). If that sounds like hyperbole, try it. The three types of fish change frequently, sometimes throughout the day, but both times I've ordered it, I've been delighted by halibut, bigeye tuna and kampachi. The slices are gently draped over seasoned koshihikari rice, nestled in with avocado, pickles and a wobbly egg, precisely poached in an immersion circulator. Swirl it all together with a dash of soy sauce, and savor it while sitting on a bench overlooking the Bay. Depending on when you visit Nopa Fish, a bench might be the extent of the seating that is available to you. Two communal tables can accommodate around 20 customers, and although Nopa Fish staff do an admirable job of helping to bus and turn seats, it can be a lousy game of hover-and-wait during the lunch rush. Unless you show up at 3 p.m., it is not a spot for a leisurely catch up. This, to me, is the slight tension inherent in the Ferry Building's new schema. Management is stacking the landmark with restaurants serving destination-worthy food, but they don't always have welcoming physical spaces to match. Nopa Fish's layout would be perfect if 85% of its business was fresh fish sales, but it just isn't so. Right next door to Nopa Fish is chef Nite Yun's acclaimed Cambodian spot Lunette, which opened in a space formerly occupied by a butcher shop. When my mother wanted to host a birthday lunch for six family members there, I advised against it, despite the fact that it's gotten even better since my colleague Cesar Hernandez raved about it last year. With counter service and just 30 seats, would a party of seven seniors be able to secure a table? And if so, would they feel comfortable lingering and celebrating? Nopa Fish is worth a visit, but temper your expectations about the dining experience. On a Saturday, 20,000 visitors pass through the Ferry Building. That's terrific news for Jossel, but you're competing with all of them for a seat. Nopa Fish Hours: 11 a.m.-7 p.m. Monday-Friday; 9 a.m.-7 p.m. Saturday (fish market only from 9-10 a.m.); Sunday and expanded hours coming soon Noise level: Moderate Meat-free options: Crispy tofu sandwich ($18, vegan); summer salad ($12) Drinks: A California white, rosé and chilled red are available by the glass ($15-$18); housemade lemonade, strawberry limeade and Arnold Palmers ($6-$7) Best practices: If you're coming during the lunch rush, be prepared to either take your order to-go and sit elsewhere in the Ferry Building or do the awkward hover-and-pounce dance. After 2 p.m., seating should be wide open.
Business Wire
a few seconds ago
- Business Wire
Air Industries Group Announces Financial Results for the Three and Six Months Ended June 30, 2025
BAY SHORE, N.Y.--(BUSINESS WIRE)-- Air Industries Group ('Air Industries') (NYSE American: AIRI), a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors, today announced Financial Results for the Three and Six months ended June 30, 2025. Second Quarter 2025 Financial Highlights Net sales: $12.7 million, a decrease of $0.9 million or 6.7% decrease from $13.6 million in Q2 2024. Gross Profit: $2.0 million, down $0.6 million or 23.3% from $2.6 million in Q2 2024. Gross margin decreased to 16.0%, a decrease of 350 basis points from 19.5% in Q2 2024. Operating Expenses: $2.0 million, up $0.1 million or 6.8% from $1.9 million in Q2 2024. Operating income: $8,000, compared to $752,000 in Q2 2024. Net loss: $422,000, compared to net income of $298,000 in Q2 2024. Adjusted EBITDA: $893,000, a decrease from $1,413,000 in Q2 2024. Second Quarter Summary Income Statement Second Quarter June (Unaudited) 2025 2024 Net Sales $ 12,659,000 $ 13,572,000 Cost of Sales 10,631,000 10,928,000 Gross Profit 2,028,000 2,644,000 Gross Margin 16.0 % 19.5 % Operating Expense 2,020,000 1,892,000 Operating Income 8,000 752,000 Interest Expense (446,000 ) (474,000 ) Other Income (net) 16,000 20,000 Income (Loss) before Income Taxes (422,000 ) 298,000 Income Taxes - - Net Income (Loss) $ (422,000 ) $ 298,000 Net Income (Loss) per Share $ (0.11 ) $ 0.09 Reconciliation of EBITDA To GAAP Net Income (Loss) $ (422,000 ) $ 298,000 Interest Expense 446,000 474,000 Depreciation 656,000 574,000 Amortization 17,000 17,000 Stock Compensation 196,000 50,000 Adjusted EBITDA $ 893,000 $ 1,413,000 All Amounts are Unaudited. Expand First Half 2025 Results: Net sales: $24.8 million, down $2.8 million or 10.2% decrease from $27.6 million in the first half of 2024. Gross Profit: $4.1 million a decrease of $0.5 million or 10.7% from $4.6 million in the first half of 2024. Gross margin was 16.4%, compared to 16.5% in 2024. Operating Expenses: $4.8 million, up $0.7 million or 18.3% from $4.1 million in the first half of 2024, with $0.6 million of the increase driven by non-cash stock compensation expense. Operating loss: $0.7 million, compared to operating income of $0.5 million in the first half of 2024. Net loss: $1.4 million, compared to a net loss of $0.4 million in the first half of 2024. Adjusted EBITDA: $1.5 million a decrease from $1.8 million in the first half of 2024. First Half 2025 Summary Income Statement Lou Melluzzo, Chief Executive Officer of Air Industries Group, commented: 'The second quarter of 2025 presented challenges, primarily delays in customer orders and extended lead times from subcontractors, which impacted our results. These issues, combined with higher non-cash stock compensation expenses, contributed to a net loss for the quarter. However, Adjusted EBITDA for the first half remained positive, reflecting our ability to manage costs. Looking to the second half, we are adjusting our outlook to reflect the impact of these issues and now expect overall second-half results in 2025 to be lower than the first half, with our fourth quarter expected to be the strongest by far. At the same time, we have implemented cost-saving initiatives, including a workforce reduction that should reduce annual payroll by approximately $1.0 million.' Mr. Melluzzo further commented: 'Despite recent headwinds, I believe our long-term business outlook remains strong. In early July 2025, we successfully completed an at-the-market ('ATM') offering, raising nearly $4.0 million in gross proceeds through the sale of 1,003,653 common shares—further strengthening our balance sheet. Our backlog remains at record levels, reflecting sustained demand for our products, the benefits of which will be realized in fiscal 2026 and beyond. I remain confident that the underlying strength of our business will drive continued progress and deliver lasting value to our shareholders.' Conference Call Information Air Industries Group will host a conference call to discuss Financial Results for the Second Quarter and Six Months of 2025 on Thursday August 14 th at 4:30 pm Eastern. The conference call-in number is 877–524–8416 ABOUT AIR INDUSTRIES GROUP Air Industries Group is a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors. Its products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. Whether it is a small individual component or complete assembly, its high quality and extremely reliable products are used in mission critical operations that are essential for the safety of military personnel and civilians. FORWARD LOOKING STATEMENTS Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, earnings and Adjusted EBITDA, the ability to realize firm backlog and projected backlog, cost cutting measures, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of projects due to variability in size, scope and duration, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. NON-GAAP FINANCIAL MEASURES The Company uses Adjusted EBITDA, a Non-GAAP financial measure as defined by the SEC, as a supplemental profitability measure because management finds it useful to understand and evaluate results, excluding the impact of non-cash depreciation and amortization charges, stock based compensation expenses, and nonrecurring expenses and outlays, prior to consideration of the impact of other potential sources and uses of cash, such as working capital items. This calculation may differ in method of calculation from similarly titled measures used by other companies and may be different than the EBITDA calculation used by our lenders for purposes of determining compliance with our financial covenants. This Non-GAAP measure may have limitations when understanding performance as it excludes the financial impact of transactions such as interest expense necessary to conduct the Company's business and therefore are not intended to be an alternative to financial measure prepared in accordance with GAAP. The Company has not quantitatively reconciled its forward looking Adjusted EBITDA target to the most directly comparable GAAP measure because items such as amortization of stock-based compensation and interest expense, which are specific items that impact these measures, have not yet occurred, are out of the Company's control, or cannot be predicted. For example, quantification of stock-based compensation is not possible as it requires inputs such as future grants and stock prices which are not currently ascertainable. Anyone wishing to contact us or send a message can also do so by visiting:
Business Wire
a few seconds ago
- Business Wire
WELL Health Reports Record Revenue, Adjusted EBITDA, and Adjusted Net Profit in Q2-2025, Upgrades Guidance, and Delivers First-Ever Quarter With More Than 1 Million Patient Visits in Canada
VANCOUVER, British Columbia--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce its interim consolidated financial results for the quarter ended June 30, 2025. Hamed Shahbazi, Chairman and CEO of WELL commented, 'I am very proud of our performance this quarter as it reflects a very significant milestone in our history with best-ever performances across most of our key financial metrics. We delivered record performances across Revenue, Adjusted EBITDA, Adjusted Net Income, and patient visits. Furthermore, we would have reported best-ever Free Cash Flow Available to Shareholders had we not had elevated cash taxes and capital expenditures due to new investments made in our Canadian clinics, executive health and longevity health portfolios, which have historically delivered excellent returns on capital invested (ROIC). Importantly, we also delivered $17M in IFRS net profit for the quarter demonstrating our ability to deliver on all key adjusted and non-adjusted metrics. I'm also very pleased to commemorate that we delivered more than 1 million patient visits in Canada during the quarter for the first time ever reflecting 38% YoY growth; approximately a third of which came from organic growth. It's important to remember the significance of each of those visits and how vital it can be to a person's health and wellness. This awareness, along with our growing scale and relevance in the healthcare ecosystem, is top of mind for us. We think about it every day as we are committed to making the investments that are designed to help healthcare providers deliver the best care and patient outcomes possible. One positive by-product of our investments is the growing productivity of our providers. The average provider at WELL grew its number of patient visits by 22%. While there are many contributors to this improvement, we believe improved tooling and technology to be one of those key reasons.' Mr. Shahbazi further added, "We are also very pleased to report our first quarter with the inclusion of HEALWELL AI, a company that we helped launch and incubate almost two years ago and in which we took a majority voting control position this past April. Yesterday HEALWELL reported record financial performance along with its first profitable quarter on an Adjusted EBITDA basis and signalled its intent to become a pure-play SaaS and Services company now that it has achieved significant scale in delivering data science and healthcare software expertise to large enterprise customers in 11 countries globally. In parallel, we continue to evaluate strategic alternatives for our U.S. assets to simplify our business and sharpen our focus on our core Canadian operations. Across the WELL ecosystem, our teams are focused on driving sustainable, profitable growth and delivering meaningful impact through technology, innovation, and operational excellence.' Eva Fong, WELL's Chief Financial Officer, commented, 'Our second quarter results demonstrate the strength of our operating model and disciplined approach to capital allocation. Year to date, we have completed fourteen transactions and are pleased to report fifteen signed LOIs representing approximately $134 million in revenues. Our high-quality pipeline of acquisition opportunities mostly includes targets across Canadian Clinics and WELLSTAR. Also, notably our WELLSTAR platform delivered another strong 'Rule of 40' performance with strong organic revenue growth and healthy Adjusted EBITDA margins, while executing on its M&A pipeline. WELLSTAR's goal is to exceed $100 million in revenues next year with continued strong margins and growth metrics. Overall, we remain committed to improving margin profile and operating leverage across the organization, while evaluating strategic opportunities to streamline and optimize our portfolio. With a strong balance sheet and increasing cash generation, we are well-positioned to support long-term growth and return value to shareholders.' Second Quarter 2025 Financial Highlights: WELL achieved record quarterly revenue of $356.7 million in Q2-2025, an increase of 57% compared to revenue of $227.3 million generated in Q2-2024. This growth was mainly driven by organic growth, acquisitions that have occurred over the last twelve months and the addition of $40.5 million of revenue in Q2-2025 from the inclusion of HEALWELL, as per IFRS reporting requirements following the company's execution of a call option to acquire voting shares of HEALWELL on April 1, 2025, relating to our majority voting position with HEALWELL. Excluding the impact of 'CM Deferrals', revenue would have reached $347.0 million, representing a 53% increase compared to the previous year. Adjusted Gross Profit (1) was $158.7 million in Q2-2025, an increase of 73% compared to Adjusted Gross Profit of $91.5 million in Q2-2024. Adjusted Gross Margin (1) percentage was 44.5% during Q2-2025 compared to Adjusted Gross Margin percentage of 40.3% in Q2-2024. The increase in Adjusted Gross Margin percentage was primarily driven by revenue mix and the addition of higher margin HEALWELL revenue, while being offset by the addition of lower margin Provider Staffing revenue from the acquisition of Harmony in January 2025. Adjusted EBITDA (1) was $49.7 million in Q2-2025, an increase of 231% compared to Adjusted EBITDA of $15.0 million in Q2-2024. Excluding the impact of CM Deferrals, Adjusted EBITDA would have reached $40.0 million, representing a 166% increase compared to the previous year. Adjusted EBITDA Attributable to WELL shareholders was $37.5 million in Q2-2025, an increase of 215% compared to Adjusted EBITDA Attributable to WELL shareholders of $11.9 million in Q2-2024. Adjusted Net Income (1) was $25.8 million, or $0.10 per share in Q2-2025, compared to Adjusted Net Income of $4.1 million, or $0.02 per share in Q2-2024. Free Cash Flow Available to Shareholders (or FCFA2S) was $11.7 million in Q2-2025 an increase of 34% compared to FCFA2S of $8.7 million in Q2-2024. Note that FCFA2S was impacted by elevated cash taxes and capital expenditures which were focused on investments in upgrading our clinical portfolio. Segmented Revenue: Canadian Patient Services revenue was $114.5 million in Q2-2025, an increase of 49% compared to $76.7 million in Q2-2024. U.S. Patient Services revenue was $184.8 million in Q2-2025, an increase of 38% compared to $133.7 million in Q2-2024. WELLSTAR, the Company's pure-play SaaS technology subsidiary, achieved revenue of $15.2 million in Q2-2025, an increase of 49% compared to $10.2 million in Q2-2024. WELLSTAR's growth was driven by healthy organic growth and acquisitions. Second Quarter 2025 Patient Visit Metrics: WELL achieved a total of 1.7 million patient visits in Q2-2025, an increase of 21% compared to 1.4 million patient visits in Q2-2024. Canadian Patient Services visits increased 38% while US Patient Services visits decreased 1%, on a year-over-year basis. Notably, the Company achieved over 1 million patient visits across its Canadian operations, a new quarterly milestone. Growth in patient visits over the past year was primarily driven by acquisitions as well as double-digit organic growth, including the clinic absorption program. In addition, WELL achieved over 2.7 million Care Interactions (2) in Q2-2025, representing approximately 10.8 million patient interactions on an annualized run-rate basis. Second Quarter 2025 Business Highlights: On April 1, 2025, the Company and the pre-HEALWELL founders amended the terms of the conditional call option held by the Company to acquire up to 30.8 million Class A Subordinate Voting Shares of HEALWELL at $0.125 per share and 30.8 million Class B Multiple Voting shares of HEALWELL at $0.0001 per share such that it became exercisable, and the Company exercised the call option to acquire such shares for total consideration of $3.9 million. On April 1, 2025, the release conditions were satisfied related to the Company's January 21, 2025, subscription for HEALWELL shares and the Company received 0.5 million Class A voting shares and 0.25 million share purchase warrants with each warrant exercisable into one Class A Subordinate Voting share at $2.50 per share for a period of 36 months in accordance with the terms of the subscription agreement. As of April 1, 2025, the Company held 97.2 million Class A Subordinate Shares and 30.8 million Class B Multiple Voting shares of HEALWELL, representing approximately 37% of the economic interest and approximately 69% of the voting rights in HEALWELL on a non-diluted basis. As a result, the Company obtained control of HEALWELL under IFRS, and accordingly, began to consolidate the financial results of HEALWELL as a subsidiary of the Company effective April 1, 2025. On May 6, 2025, the Company announced the rebranding of its cybersecurity division as CYBERWELL and the appointment of Jeffrey Engle as CEO. CYBERWELL consolidates four firms: Source44, SeekIntoo, Cycura, and Proack Security into a unified cybersecurity company. The division will focus on recurring revenue, acquisitions, and international expansion. WELL noted plans for CYBERWELL to potentially be spun out in the future and serve as a key growth engine. On May 7, 2025, WELLSTAR announced the launch of Nexus AI, a new AI-powered clinical documentation solution available across Canada. The product is initially focused on AI scribing and will expand through partnerships across the WELL ecosystem. Nexus AI is supported by government funding for up to 10,000 providers through Canada Health Infoway's AI Scribe pilot program. On May 28, 2025, the Company announced that subsidiaries of HEALWELL and WELLSTAR, Intrahealth, Pentavere, and OceanMD, were selected as recipients of Canada Health Infoway's 2025 Vendor Innovation Program. The program supports the development and implementation of real-world interoperability solutions aligned with national digital health priorities. The selected projects aim to enhance data quality, care coordination, and access to standardized health information across Canada, with deployments planned in five provinces. Three of the eight recipients are affiliated with the WELL and HEALWELL group. On June 24, 2025, the Company announced the availability of over 45,000 new primary care patient openings across its clinic network in Ontario, Alberta, and Manitoba. The expansion is enabled by investments in physician recruitment, including the onboarding of internationally trained medical graduates, and the implementation of digital infrastructure powered by WELLSTAR Technologies. The Company's National Patient Registration system, supported by OceanMD's eForms, online booking, and automated triage tools, is streamlining access and enabling clinics to accelerate the creation of new patient panels. Events Subsequent to June 30, 2025: On July 8, 2025, the Company announced the completion of two clinic acquisitions in British Columbia, effective July 1, 2025. The acquired clinics include a personalized health clinic in Vancouver and a multidisciplinary clinic in Burnaby, expanding the Company's presence in preventative health and specialty care. On July 8, 2025, the Company announced an expansion and extension of its senior secured credit facility, led by Royal Bank of Canada, increasing total capacity to approximately $200 million and extending the maturity to 2027. The revised facility converts the accordion feature into a revolving credit line, enhancing the Company's financial flexibility to support continued growth. On July 15, 2025, the Company announced that its majority-owned subsidiary, WELLSTAR Technologies Corp., executed three letters of intent for acquisitions expected to contribute approximately $15 million in ARR, $16 million in annual revenue, and over $5 million in Adjusted EBITDA on a run-rate basis. The targets deliver high-margin SaaS solutions that expand WELLSTAR's clinician enablement platform and support its strategy of disciplined, accretive growth. On July 16, 2025 HEALWELL acquired the remaining 49% of Pentavere Research Group Inc. ('Pentavere'), by exercising a call option that it had previously negotiated at the time of its original acquisition of a majority interest in Pentavere in 2023. Pursuant to the call option, HEALWELL acquired all of the remaining issued and outstanding shares of Pentavere for an aggregate purchase price of $13,978 which was satisfied with the issuance of 10,161,562 HEALWELL Class A Subordinate Voting Shares. With 100% ownership of Pentavere, HEALWELL intends to deepen integration between its AI businesses and accelerate commercialization of AI products across healthcare offerings. Outlook: WELL intends to continue its focus on maintaining strong performance, while strategically enhancing operations in the pursuit of organic growth and profitability. WELL is expecting its momentum to continue in the second half of the year across its key business units. WELL's objective is to invest in and achieve significant growth while effectively managing its costs and delivering cash flow to shareholders. Management is pleased to reaffirm its 2025 annual guidance for revenue to be between $1.40 billion to $1.45 billion, representing 52% to 58% annual growth compared to 2024. Excluding the impact of the CM Deferrals, the Company's annual revenue guidance would be between $1.35 billion to $1.40 billion. This annual revenue guidance only includes announced acquisitions; however, WELL expects to be in the upper half of this guidance range with the inclusion of planned acquisitions in the second half of the year. Furthermore, management is pleased to increase its guidance for annual Adjusted EBITDA to be in the upper half of its previously provided guidance of $190 million to $210 million. Excluding the impact of CM Deferrals, the Company is similarly improving its guidance for annual Adjusted EBITDA to be in the upper half of its previously provided guidance of $140 million to $160 million. This improvement of the Company's annual Adjusted EBITDA guidance only includes announced acquisitions. WELL continues to allocate capital thoughtfully in order to activate both organic and inorganic growth. The Company expects to continue to fund its acquisitions from its own cash flow as well as planned divestitures ensuring compounding gains over time on a per share basis. The Company also continues to focus most of its M&A and capital allocation activity in Canada where it is experiencing its strongest returns. Conference Call: WELL will release its Second Quarter 2025 financial results for the period ended June 30, 2025, on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). Please use the following dial-in numbers: 1-800-717-1738 (Toll Free) or 1-289-514-5100 (International). The conference call will also be simultaneously webcast and can be accessed at the following audience URL: Selected Unaudited Financial Highlights: Please see SEDAR for complete copies of the Company's condensed interim consolidated financial statements and interim MD&A for the quarter ended June 30, 2025. Footnotes: Non-GAAP financial measures and ratios. In addition to results reported in accordance with IFRS, the Company uses certain non-GAAP financial measures as supplemental indicators of its financial and operating performance. These non-GAAP financial measures include Adjusted Net Income, Adjusted Net Income Per Share, Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted Free Cash Flow. The Company believes these supplementary financial measures reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. Adjusted Net Income and Adjusted Net Income per Share The Company defines Adjusted Net Income as net income (loss), after excluding the effects of share-based payments, amortization of acquired intangible assets, time-based earnout expense, change in fair value of investments, change in fair value of derivative liability, non-controlling interests, and revenue precluded from recognition under IFRS 15 that relates to certain patient services revenue that the Company believes should be recognized as revenue based on its contractual relationships. Adjusted Net Income Per Share is Adjusted Net Income divided by weighted average number of shares outstanding. The Company believes that these non-GAAP financial measures provide useful information to analyze our results, enhance a reader's understanding of past financial performance and allow for greater understanding with respect to key metrics used by management in decision making. More specifically, the Company believes Adjusted Net Income is a financial metric that tracks the earning power of the business that is available to WELL shareholders. EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are non-GAAP measures. EBITDA represents net income (loss) before interest, taxes, depreciation, and amortization. The Company defines Adjusted EBITDA as EBITDA (i) less net rent expense on premise leases considered to be finance leases under IFRS and (ii) before transaction, restructuring, and integration costs, time-based earn-out expense, change in fair value of investments, change in fair value of derivative liability, share of loss of associates, foreign exchange gain/loss, and share-based payments, (iii) revenue precluded from recognition under IFRS 15 that relates to certain patient services revenue that the Company believes should be recognized as revenue based on its contractual relationships, and (iv) gains/losses that are not reflective of ongoing operating performance. The Company considers Adjusted EBITDA a financial metric that measures cash that the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives. EBITDA and Adjusted EBITDA should not be considered alternatives to net income (loss), cash flow from operating activities or other measures of financial performance in accordance with IFRS. Adjusted Gross Profit and Adjusted Gross Margin The Company defines Adjusted Gross Profit as revenue less cost of sales (excluding depreciation and amortization) and Adjusted Gross Margin as adjusted gross profit as a percentage of revenue. Adjusted gross profit and adjusted gross margin should not be construed as an alternative for revenue or net income (loss) determined in accordance with IFRS. The Company does not present gross profit in its consolidated financial statements as it is a non-GAAP financial measure. The Company believes that adjusted gross profit and adjusted gross margin are meaningful metrics that are often used by readers to measure the Company's efficiency of selling its products and services. Adjusted Free Cash Flow The Company defines Adjusted Free Cash Flow Attributable to Shareholders as Adjusted EBITDA Attributable to Shareholders, less cash interest, less cash taxes and less capital expenditures. Adjusted Net income, Adjusted Net Income per Share, Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted Free Cash Flow are not recognized measures for financial statement presentation under IFRS and do not have standardized meanings. As such, these measures may not be comparable to similar measures presented by other companies and should be considered as supplements to, and not as substitutes for, or superior to, the corresponding measures calculated in accordance with IFRS. Total Care Interactions are defined as Total Patient Visits plus Technology Interactions plus Billed Provider Hours. WELL HEALTH TECHNOLOGIES CORP. Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 165 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about WELL, please visit: Forward-Looking Statements This news release may contain 'Forward-Looking Information' within the meaning of applicable Canadian securities laws, including, without limitation: information regarding the Company's goals, strategies and growth plans, including expected acquisitions and divestitures Company and HEALWELL; expectations regarding continued revenue and EBITDA growth; the Company's expectations pertaining to annual guidance for annual revenue and Adjusted EBITDA; the expected benefits and synergies of completed acquisitions; capital allocation plans in the form of more acquisitions or share repurchases; expected patient visits; and the expected financial performance as well as information in the 'Outlook' section herein. Forward-Looking Information are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. Forward-Looking Information generally can be identified by the use of forward-looking words such as 'may', 'should', 'will', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-Looking Information involve known and unknown risks, uncertainties and other factors that may cause future results, performance, or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by the Forward-Looking Information and the Forward-Looking Information are not guarantees of future performance. WELL's comments expressed or implied by such Forward-Looking Information are subject to a number of risks, uncertainties, and conditions, many of which are outside of WELL 's control, and undue reliance should not be placed on such information. Forward-Looking Information are qualified in their entirety by inherent risks and uncertainties, including: risks regarding the timing and amount of recognition or revenue and earnings; direct and indirect material adverse effects from adverse market conditions; risks inherent in the primary healthcare sector in general; regulatory and legislative changes; that future results may vary from historical results; inability to obtain any requisite future financing on suitable terms; any inability to realize the expected benefits and synergies of acquisitions; that market competition may affect the business, results and financial condition of WELL and other risk factors identified in documents filed by WELL under its profile at including its most recent Annual Information Form and its Management, Discussion and Analysis. Except as required by securities law, WELL does not assume any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise. This news release contains future-oriented financial information and financial outlook information (collectively, 'FOFI') about estimated annual run-rate revenue and Adjusted EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set out in the above paragraph. The actual financial results of WELL may vary from the amounts set out herein and such variation may be material. WELL and its management believe that the FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgments. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, WELL undertakes no obligation to update such FOFI. FOFI contained in this news release was made as of the date hereof and was provided for the purpose of providing further information about WELL's anticipated future business operations on an annual basis. Readers are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein. Neither the TSX nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
